Invasive Breast Cancer Clinical Trial
Official title:
Identification of Novel Genetic Risk Factors That Contribute to the Risk for Breast Cancer
The purpose of this study is to identify novel genetic factors which distinguish breast cancer in younger women compared to older women. By identifying these novel genetic factors we believe more specific therapies can be developed and breast cancer may be prevented among women with an increased cancer risk. A woman does not have to live in St. Louis to participate.
Breast cancer takes its greatest toll on younger women, as it is the leading category of cancer deaths for women 20-39 years of age. Sadly, survival rates are lowest among women diagnosed at a young age. This impact is most significant among African-American women who have the highest incidence and mortality rate among women less than 45 years of age. The goal of our program is to identify the genetic factors which distinguish breast cancer in younger women compared to older women. Women who were diagnosed with invasive breast cancer 40 years of age or younger are invited to participate. The age at diagnosis is used to determine eligibility, not a woman's current age. Women who have undergone genetic testing of the BRCA1, BRCA2, p53, pTEN, e-cadherin, or LKB1 genes are eligible to participate. Young women with breast cancer are asked to: sign a consent form, submit a sample of blood, release their cancer related records, and answer some family history questions. We will use a family based case control approach in our analysis. As such, if a woman's parents are living, they will be invited to participate as a "comparison" group. The parents are asked to: sign a consent form, submit a sample of blood, and release any cancer records. A woman does not have to live in St. Louis to participate. All study related materials can be mailed directly to the young woman or her parents. There is no expense to the family. All materials are kept strictly confidential and participation is completely voluntary. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03595592 -
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT06158217 -
Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
|
||
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT02773784 -
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
|
||
Recruiting |
NCT01509781 -
Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study
|
Phase 3 | |
Completed |
NCT04478669 -
Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
|
||
Recruiting |
NCT04553770 -
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04677816 -
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
|
Phase 2 | |
Terminated |
NCT01934335 -
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
|
Phase 2 | |
Completed |
NCT00507611 -
Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients
|
N/A | |
Completed |
NCT00581750 -
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
|
||
Completed |
NCT03304171 -
Overall Diet Quality and Breast Cancer Risk
|
N/A | |
Completed |
NCT03709186 -
Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
|
||
Terminated |
NCT03361800 -
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
|
Early Phase 1 | |
Recruiting |
NCT04648904 -
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT06328465 -
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
|
N/A | |
Active, not recruiting |
NCT03109522 -
Axillary Reverse Mapping (ARM) Technique
|
N/A | |
Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
Recruiting |
NCT03497702 -
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
|
Phase 2 |